1ˢᵗ International SIR
Workshop on Osteoarthritis

The challenge of early Osteoarthritis

sir
Società Italiana
Reumatologia

ROME
December 12-13, 2014

Congress venue:
NH Hotel Leonardo da Vinci

Principal Investigator:
Alberto Migliore

SCIENTIFIC PROGRAM COMMITTEE
G. Bianchi, L. Di Matteo, G. Bagnato, M. Scarpellini, R. Ramonda, G. Minisola, D. Diracoglu,
G. Herrero Beaumont, X. Chevalier, N. Akkoc, E. Maheu, N. Damjanov, R. Ionescu, R. Rashkov,
J. Branco, D. Babic Naglic, L. Collaku

FRIDAY, DECEMBER 12

15.00-17.00 | *Promoting a prospective cohort study of OA in East and South countries of Europe*

Introduction - **M. Matucci Cerinic**

Why a Mediterranean and East countries shared data base with a cohort project?
A. Migliore

What have we learned from the OARSI-Initiative? - **E. Bizzi**

What have we learned from the CHECK cohort study? - **J. Branco**

What have we learned from the French cohort "KHOALA study"? - **E. Maheu**

Discussion of all panelists:

The discussion should focus on:

- Which topics we can consider already known?
- New items to investigate, especially for early OA

17.00-17.30 | *Coffee break*

17.30-19.30 | *Why a Mediterranean and East countries shared data base*

May Ultrasound be helpful to detect early phases of OA? - **N. Damjanov**

State of the art in imaging MRI to detect early OA - **R. Ramonda**

State of the art in soluble biomarkers to detect early OA - **G. Herrero Beaumont**

Discussion of all panelists:

The discussion should focus on:

- Which markers may be considered theoretically the best candidate to study in EOA?
- Which markers may be considered more affordable in our cohort study for early OA?

Presentation of a Mediterranean and East countries shared data base - **A. Migliore, C.A. Scirè**

20.30 | *Social Dinner*

SATURDAY, DECEMBER 13

8.30-10.00 | Finalizing the definition of "early symptomatic OA" and its red flags for referral to rheumatologist - **L. Carmona**

10.00-10.30 | *Coffee break*

10.30-11.30 | *Validating ESOA in Mediterranean and East European countries*
Chairmen: L. Carmona, A. Migliore

Methodology of the validation

Sample size

Management of the data of a single country and of the whole cohort

Identifying the patients' characteristics of South and East Europe an cohort
Chairmen: N. Damjanov, G. Herrero Beaumont, A. Migliore

Discussion of all panelists:

Aim

Inclusions criteria

Sample size

Primary endpoints

Secondary endpoints

Time plan

Fund raising - **M. Matucci Cerinic**

Involving Horizon 2020 and national bodies - **P. Conti**

13.30 | *Lunch*

SPEAKERS

Akkok Nurullah - *Istanbul (Turkey)*	Diracoglu Demirhan - *Istanbul (Turkey)*
Babic Naglic Durda - *Zagreb (Croatia)*	Frediani Bruno - *Siena (Italy)*
Bagnato Gianfilippo - *Messina (Italy)*	Herrero Beaumont Gabriel - *Madrid (Spain)*
Bizzi Emanuele - *Rome (Italy)*	Ionescu Ruxandra - *Bucharest (Romania)*
Branco Jaime - *Lisbon (Portugal)*	Maheu Emmanuel - *Paris (France)*
Canhão Helena - *Lisbon (Portugal)*	Martusevitch Natalia - *Minsk (Belarius)*
Carmona Loreto - *Madrid (Spain)*	Matucci Cerinic Marco - *Florence (Italy)*
Collaku Ledio - *Tirana (Albania)*	Migliore Alberto - *Rome (Italy)*
Conti Pietro - *Milan (Italy)*	Ramonda Roberta - *Padova (Italy)*
Damjanov Nemanja - *Belgrade (Serbia)*	Scarpellini Magda - *Magenta (Italy)*
Denisov Lev - *Moscow (Russia)*	Scirè Carlo Alberto - *Milan (Italy)*
Di Matteo Luigi - *Pescara (Italy)*	